Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Jared Baeten, University of Washington
ClinicalTrials.gov Identifier:
NCT00527618
First received: September 7, 2007
Last updated: January 18, 2013
Last verified: January 2013

September 7, 2007
January 18, 2013
December 2007
March 2011   (final data collection date for primary outcome measure)
  • The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. [ Time Frame: 26 weeks (12 weeks per drug intervention) ] [ Designated as safety issue: No ]
    Weekly measurements of plasma HIV-1 RNA on each drug were compared. The primary analysis was of the average difference in plasma HIV-1 RNA on valacyclovir and acyclovir as determined by a linear mixed model. The median of the average per-participant plasma HIV-1 RNA levels on valacyclovir and valacyclovir is also listed.
  • The Genital HSV Shedding Rate While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. [ Time Frame: The first four weeks of each intervention ] [ Designated as safety issue: No ]
    HSV DNA quantitated from daily self-collected genital swabs for the first four weeks of each drug intervention. The shedding rate was determined by the combined number of swabs with HSV detected divided by the combined number of swabs collected from participants, multiplied by 100.
The primary endpoints are the presence and quantity of genital HSV and the level of HIV-1 RNA in plasma and genital secretions of participants while on 400 mg twice daily of acyclovir versus while on 1000 mg twice daily of valacyclovir. [ Time Frame: 26 weeks ]
Complete list of historical versions of study NCT00527618 on ClinicalTrials.gov Archive Site
  • The Effect of Valacyclovir 1 Gram Twice Daily Compared to Acyclovir 400 mg Twice Daily on the Percentage of Days With Genital Herpes Lesions. [ Time Frame: 26 weeks (12 weeks per drug intervention) ] [ Designated as safety issue: No ]
    The percentage of days with genital herpes lesions was determined by the combined diary days in which genital lesions were recorded divided by the combined number of diary days for participants in the first four weeks of each drug intervention, multiplied by 100.
  • The Effect of Valacyclovir 1 g Twice Daily Compared With Acyclovir 400 mg Twice Daily on the Quantity of Genital HSV Detected During Shedding Episodes. [ Time Frame: The first four weeks of each intervention ] [ Designated as safety issue: No ]
    HSV DNA was quantitated from daily self-collected genital swabs for the four weeks of each drug intervention. The quantity of genital HSV DNA present, when HSV DNA was detected, was compared.
  • The Safety of Valacyclovir 1 Gram Orally Twice Daily in HIV-1 Seropositive Persons. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Sub-Study: To Evaluate the Kinetics of Plasma HIV-1 Decline Over the First Three Days of High-dose Valacyclovir Administration. [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
    Plasma HIV-1 RNA was measured one day prior to, at initiation, and at 6, 24, 48, and 72 hours after initiating valacyclovir. Measurements at 24, 48, and 72 hours were used to determine the rate of HIV-1 RNA decline.
  • To evaluate the effect of valacyclovir 1 gram orally twice daily on prevention of days with genital herpes lesions compared with acyclovir 400 mg orally twice daily. [ Time Frame: 26 weeks ]
  • To evaluate the safety of valacyclovir 1 gram orally twice daily in HIV-1 seropositive persons. [ Time Frame: 26 weeks ]
Not Provided
Not Provided
 
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons

To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV reactivation and on plasma HIV-1 levels among HSV-2/HIV-1 co-infected individuals. The investigators hypothesize that high-dose valacyclovir will result in greater reduction in plasma HIV-1 and genital HSV reactivation.

We propose to conduct a randomized, open-label, cross-over study of 38 individuals who are HIV-1 seropositive and HSV-2 seropositive. Both men and women will be recruited for the study. Participants must not be on antiretroviral therapy and must not be planning to initiate antiretroviral therapy during the anticipated study period. Participants will be randomized 1:1 to receive acyclovir 400 mg twice daily or valacyclovir 1000 mg twice daily. After 12 weeks on the initial treatment, each participant will be crossed over to the alternative treatment arm for 12 weeks. The treatment periods will be separated by a 2-week washout period. During the first four weeks of each treatment period (i.e. weeks 1-4 and weeks 15-18), participants will provide self-collected genital swabs daily for HSV DNA quantification. Each week during the entire study period plasma samples will be collected from participants for HIV-1 RNA quantification.

Open-label acyclovir and valacyclovir will be used for this trial, as the primary outcome measures (genital HSV and plasma HIV-1) are unlikely to be influenced by knowledge of treatment assignment. However, laboratory staff performing plasma HIV-1 and genital HSV measurements will not be aware of treatment assignment.

Optional Sub-Study A: Sub-study A will be offered to study participants. The purpose of sub-study A is to measure the effect of valacyclovir twice daily on plasma HIV-1 replication.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Genital Herpes
  • HIV Infection
  • Drug: valacyclovir
    valacyclovir 1000 mg orally twice daily for 12 weeks.
    Other Name: Valtrex
  • Drug: acyclovir
    acyclovir 400 mg orally twice daily for 12 weeks.
    Other Name: Zovirax
  • Active Comparator: Standard-dose acyclovir
    acyclovir 400 mg orally twice daily for 12 weeks.
    Intervention: Drug: acyclovir
  • Experimental: High-dose valacyclovir
    valacyclovir 1000 mg orally twice daily for 12 weeks.
    Intervention: Drug: valacyclovir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 years or older
  • Documented HIV-1 seropositive
  • Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period
  • Detectable HIV-1 plasma viral load
  • HSV-2 seropositive as determined by western blot
  • Not intending to move out of the area for the duration of study participation
  • Willing and able to provide independent written informed consent
  • Willing and able to undergo clinical evaluations
  • Willing and able to take study drug as directed
  • Willing and able to adhere to follow-up schedule

Exclusion Criteria:

  • Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir
  • Planned open label use of acyclovir, valacyclovir, or famciclovir
  • History of evidence of CMV disease
  • Known medical history of seizures
  • Known renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl
  • AST or ALT greater than 3 times upper limit of normal
  • Hematocrit less than 30 %
  • Neutropenia, defined as absolute neutrophil count less than 1000
  • Thrombocytopenia, defined as platelet count less than 75,000
  • History of thrombotic microangiopathy
  • For women, pregnancy as confirmed by a urine pregnancy test
  • Any other condition which, in the opinion of the principal investigator, may compromise the ability to follow study procedures and complete the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00527618
31203-D, GSK VAL111009 - VAL140
No
Jared Baeten, University of Washington
University of Washington
GlaxoSmithKline
Principal Investigator: Jared Baeten, MD, PhD University of Washington
Study Director: Anna Wald, MD, MPH University of Washington
University of Washington
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP